Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference36 articles.
1. Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics. 2013;31(8):663–75.
2. The National Institute for Health and Care Excellence. NICE DSU technical support document 14: Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data. 2022. https://www.sheffield.ac.uk/sites/default/files/2022-02/TSD14-Survival-analysis.updated-March-2013.v2.pdf. Accessed 3 Apr 2022.
3. Djalalov S, Beca J, Ewara EM, Hoch JS. A comparison of different analysis methods for reconstructed survival data to inform cost-effectiveness analysis. Pharmacoeconomics. 2019;37(12):1525–36.
4. Gibson E, Koblbauer I, Begum N, Dranitsaris G, Liew D, McEwan P, et al. Modelling the survival outcomes of immuno-oncology drugs in economic evaluations: a systematic approach to data analysis and extrapolation. Pharmacoeconomics. 2017;35(12):1257–70.
5. Crowther MJ, Lambert PC. A general framework for parametric survival analysis. Stat Med. 2014;33(30):5280–97.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献